Telomir Pharmaceuticals Inc. has announced new preclinical data showing that its investigational compound, Telomir-1, significantly reduces prostate-specific antigen $(PSA)$ levels in androgen-responsive human prostate cancer cells in vitro. PSA is an FDA-recognized biomarker for assessing prostate cancer treatment response, and Telomir-1 was found to lower PSA levels in a dose-dependent manner. The compound also demonstrated reductions in cellular energy metabolism and viability. Additional previously reported preclinical studies in a mouse model showed that Telomir-1 reduced tumor volume, both as a single agent and in combination with paclitaxel, with the combination resulting in no treatment-related mortality. These findings are part of Telomir's ongoing preclinical development efforts as the company prepares for an investigational new drug $(IND)$ submission. The announcement did not specify if or when these results will be presented at a scientific meeting.